Thrombosis / protease

Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

CROSS REFERENCE TO RELATED APPLICATIONS This application is a 35 U.S.C. .sctn.371 U.S. national stage filing from PCT Application Ser. No. PCT/JP2004/019226 having an international filing date of Dec. 22, 2004, published under WO 2005/062054 A1 on Jul. 7, 2005, which claims priority to Japanese

Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

The invention relates to mutants of factor VII-activating protease (FSAP) and to reduced blood plasma levels of FSAP as indicators of an increased risk for the development and progression of atherothrombosis (or arterial thrombosis) and of the pathophysiological sequelae resulting

Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

The invention relates to mutants of factor VII-activating protease (FSAP) and to reduced blood plasma levels of FSAP as indicators of an increased risk for the development and progression of atherothrombosis (or arterial thrombosis) and of the pathophysiological sequelae resulting

Fibrinogenolytic proteases with thrombolytic and antihypertensive activities: medical application and novel process of expression and production

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the purification and use of a novel family of fibrinogenolytic proteases. Specifically, this invention relates to a fibrinogenolytic protease which possesses a strong beta-fibrinogenolytic activity and does not cause

Protease resistant urokinase

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND Urokinase (E.C. 3.4.21.31) is a serine protease which activates plasminogen to plasmin. The protein is synthesized in a variety of tissues including endothelium and kidney, and is excreted in trace amounts into urine. Purified urokinase exists in two active forms, a high molecular weight

Protease-activated receptor 3 and uses thereof

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

FIELD OF THE INVENTION This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins. BACKGROUND OF THE INVENTION Thrombin, a coagulation protease generated at sites of

DNA encoding a protease-activated receptor 3

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

FIELD OF THE INVENTION This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins. BACKGROUND OF THE INVENTION Thrombin, a coagulation protease generated at sites of

Immunoassays for catalytically-active, serine proteases

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND Thrombosis and thrombolysis are maintained in delicate balance by a series of high regulated enzymatic reactions. The component enzymes are are largely serine proteases which are produced as needed from zymogens, inactive forms of the enzymes which circulate in the blood at relatively

DNA encoding the human serine protease EOS

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND OF THE INVENTION Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen

Antibody immunologically reactive with serine protease EOS

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND OF THE INVENTION Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen

DNA encoding the human serine protease EOS

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND OF THE INVENTION Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen

Methods for Identifying modulators of serine protease EOS

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND OF THE INVENTION Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen

System and method for delivering protease inhibitors

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

BACKGROUND 1. Technical Field The present invention generally relates to a system and a method for delaying the dissolution of blood clots, and more particularly, the present invention provides a method and a delivery system for a material which delays the degradation of fibrin based blood clots. 2.

Mast cell protease that cleaves fibrinogen

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

FIELD OF THE INVENTION This invention relates to compositions containing a mast cell protease and its derivatives, and methods for use thereof. The mast cell protease selectively cleaves fibrinogen in vitro and in vivo. Accordingly, the compositions of the invention are useful for modulating fibrin

Therapeutic application of Kazal-type serine protease inhibitors

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

This is a national stage entry of PCT/EP2008/001009, filed Feb. 11, 2008, which claims priority to EP 07002903.8, filed Feb. 12, 2007, all of which are incorporated herein by reference. The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type

thrombosis/protease

Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease

Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis

Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations

Fibrinogenolytic proteases with thrombolytic and antihypertensive activities: medical application and novel process of expression and production

Protease resistant urokinase

Protease-activated receptor 3 and uses thereof

DNA encoding a protease-activated receptor 3

Immunoassays for catalytically-active, serine proteases

DNA encoding the human serine protease EOS

Antibody immunologically reactive with serine protease EOS

DNA encoding the human serine protease EOS

Methods for Identifying modulators of serine protease EOS

System and method for delivering protease inhibitors

Mast cell protease that cleaves fibrinogen

Therapeutic application of Kazal-type serine protease inhibitors

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası